Jackson Square Capital’s Royalty Pharma RPRX Stock Holding History

Jackson Square Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14,406	Closed	-$579K	–	134
2022 Q3	$579K	Sell	14,406 -47,556	-77%	-$2.03M	0.28%	71
2022 Q2	$2.6M	Buy	+61,962	New	+$2.54M	1.1%	27

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jackson Square Capital's RPRX Position: Q4 2022 in Review

Jackson Square Capital sold out of Royalty Pharma (RPRX) in Q4 2022, closing a stake of 14,406 shares — an estimated $579K sold.

Jackson Square Capital first reported a position in RPRX in Q2 2022 and held it in 2 quarters. The position peaked at $2.6M in Q2 2022. 334 funds tracked by Wall St. Rank hold RPRX as of Q4 2022.

Jackson Square Capital reported no remaining Royalty Pharma position as of Q4 2022 after selling out during the quarter.
Jackson Square Capital sold 14,406 Royalty Pharma shares in Q4 2022, an estimated $579K.
Jackson Square Capital first reported a position in Royalty Pharma in Q2 2022 and held it in 2 quarters.
Jackson Square Capital's Royalty Pharma position peaked at $2.6M in Q2 2022.
334 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2022.

Based on Jackson Square Capital's 13F filing for Q4 2022, filed 23 Jan 2023.